Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

I wonder are Gilead interested in us any more as they ... announcing a brand new dream deal from a third party and the HOOKIPA one dropped last night was just to save face from them.

Following the completion of the Phase 1b trial, Gilead will have the exclusive right to further develop the program.

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Poolbeg Pharma plc and HOOKIPA Pharma Inc. provided an update on their potential combination, noting Gilead Sciences Inc.'s intention to participate in a related fundraising effort with a ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

The Combined Group would also have two partnered programmes with Gilead Sciences ... for the Combined Group's shareholders. HOOKIPA is listed on the Nasdaq Capital Market under the symbol HOOK ...

The Combined Group would also have two partnered programmes with Gilead Sciences ... for the Combined Group's shareholders. HOOKIPA is listed on the Nasdaq Capital Market under the symbol HOOK ...